Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.

Trial Profile

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2011

At a glance

  • Drugs Capecitabine; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 12 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top